These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28499961)

  • 21. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
    Kosiborod M; Gomes MB; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Watada H; Shimomura I; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Khunti K;
    Cardiovasc Diabetol; 2018 Nov; 17(1):150. PubMed ID: 30486889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
    van Raalte DH; Verchere CB
    Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes.
    Rewers MJ; Pillay K; de Beaufort C; Craig ME; Hanas R; Acerini CL; Maahs DM;
    Pediatr Diabetes; 2014 Sep; 15 Suppl 20():102-14. PubMed ID: 25182311
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial.
    Hermanns N; Ehrmann D; Schall S; Maier B; Haak T; Kulzer B
    Diabet Med; 2017 Aug; 34(8):1084-1091. PubMed ID: 28257159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes.
    Danne T; Bangstad HJ; Deeb L; Jarosz-Chobot P; Mungaie L; Saboo B; Urakami T; Battelino T; Hanas R;
    Pediatr Diabetes; 2014 Sep; 15 Suppl 20():115-34. PubMed ID: 25182312
    [No Abstract]   [Full Text] [Related]  

  • 30. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
    Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
    Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities.
    Khunti K; Heerspink HJL; Lam CSP; Nicolucci A; Ramirez L; Surmont F; Fenici P; Kosiborod M
    J Diabetes Complications; 2021 Dec; 35(12):108077. PubMed ID: 34686406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
    Nicolucci A; Charbonnel B; Gomes MB; Khunti K; Kosiborod M; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Pocock S
    Diabetes Obes Metab; 2019 Nov; 21(11):2474-2485. PubMed ID: 31297947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
    Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
    BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of continuous glucose monitoring for type 2 in diabetes management and research.
    Vigersky R; Shrivastav M
    J Diabetes Complications; 2017 Jan; 31(1):280-287. PubMed ID: 27818105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
    Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
    J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ISPAD Guidelines. Managing diabetes in preschool children.
    Sundberg F; Barnard K; Cato A; de Beaufort C; DiMeglio LA; Dooley G; Hershey T; Hitchcock J; Jain V; Weissberg-Benchell J; Rami-Merhar B; Smart CE; Hanas R
    Pediatr Diabetes; 2017 Nov; 18(7):499-517. PubMed ID: 28726299
    [No Abstract]   [Full Text] [Related]  

  • 37. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of diabetes treatment with long-term glycemic patterns in patients with type 2 diabetes mellitus: A prospective cohort study.
    Luo M; Tan CS; Lim WY; Chia KS; Tang WE; Tai ES; Venkataraman K
    Diabetes Metab Res Rev; 2019 May; 35(4):e3122. PubMed ID: 30600922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.